Physicochemical characterization and dissolution properties of binary systems of pyrimethamine and 2-hydroxypropyl-β-cyclodextrin

African Journal of Biotechnology

Volumn 8, Issue 8, 2009, Pages 1651-1659

  Onyeji, Cyprian O ^a   Omoruyi, Sharon I ^a   Oladimeji, Francis A ^a   Soyinka, Julius O ^a  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

2 hydroxypropyl p cyclodextrin; Complexation; Enhanced dissolution; Physicochemical characterization; Pyrimethamine

Indexed keywords

2 HYDROXYPROPYL CYCLODEXTRIN; CYCLODEXTRIN; PYRIMETHAMINE; UNCLASSIFIED DRUG;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG SOLUBILITY; DRUG STRUCTURE; EVAPORATION; FREEZE DRYING; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; STOICHIOMETRY; X RAY DIFFRACTION;

PLASMODIUM FALCIPARUM; PROTOZOA; TOXOPLASMA GONDII;

EID: 66749122123     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Almond DS, Szwandt ISF, Edwards G, Lee MG, Winstanley PA (2000). Disposition of Intravenous pyrimethamine in Healthy Volunteers. Antimicrob. Agents Chemother. 44(6): 1691-1693.
2. Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K (2001). Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J. Pharm. Sci. 90: 690-701.
3. Baboota S, Dhaliwal M, Kohli K (2005). Physicochemical characterization, in vitro dissolution behaviour and pharmacodynamic studies of rofecoxib hydroxypropyl beta-cyclodextrin inclusion complex: A technical note. AAPS Pharm. Sci. Technol. 6(1): E83-E89.
4. Castillo JA, Canales JP, Garcia JJ, Lastres JL, Bolas F, Torrado JJ (1999). Preparation and characterization of albendazole beta- cyclodextrin complexes. Drug Dev. Ind. Pharm. 25: 1241-1248.
5. Cavallito JC, Nichol CA, Brenckman WD, Deangelis RL, Stickney DR, Simmons WS, Sigel CW (1978). Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. J. Pharmacol. Exp. Ther. 6(3): 329-337.
6. Challa R, Ahuja A, Ali J, Khar R (2005). Cyclodextrins in Drug Delivery: An Updated Review. AAPS Pharm. Sci. Tech. 06(02): E329-E357.
7. Chowdary KPR, Nalluri BN (2000). Nimesulide and beta-cyclodextrin inclusion complexes: physicochemical characterization and disso-lution rate studies. Drug Dev. Ind. Pharm. 26: 1217-1220.
8. Chulay JD, Watkins WM, Sixsmith DG (1984). Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 33: 325-330.
9. Connors KA (1997). The stability of cyclodextrin complexes in solution. Chem. Rev. 97: 1325-1357.
10. Corringan OI, Stanley T (1982). Mechanism of drug dissolution rate enhancement for beta-cyclodextrin-drug-systems. J. Pharm. Sci. 34: 621-626.
11. deAraujo MVG, Viera EKB, Lazaro GS, Conegero LS, Ferreira OP, Almeida LE, Barreto LS, da Costa NB, Gimenez IF (2007). Inclusion complexes of pyrimethamine in2-hydroxypropyl-b-cyclodextrin: Cha-racterization, phase solubility and molecular modeling. Bioorganic Med. Chem. 15: 5752-5759.
12. Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B, Nussbaum J (1992). Treatment of toxoplasmic encephalitis in patients with AIDS. Ann. Int. Med. 116: 33-43.
13. Higuchi T, Connors KA (1965). Phase solubility diagram. Adv. Anal. Chem. Instrum. 4: 17-21.
14. Khan KA (1975). The concept of dissolution efficiency. J. Pharm Pharmacol. 27: 48-49.
15. Moyano JR, Arias MJ, Gines JM, Perez JI, Rabasco AM (1997). Dissolution behavior of oxazepam in the presence of cyclodextrins: evaluation of oxazepam dimeb binary system. Drug Dev. Ind. Pharm. 23: 379-385.
16. Muller BW, Brauns U (1986). Hydroxypropyl-beta-cyclodextrin derivatives: influence of average degree of substitution on complexing ability and surface activity. J. Pharm. Sci. 75: 571-572.
17. Mura P, Adragna E, Rabasco AM, Moyano JR, Perez-Martinez JL, Arias MJ, Gines JM (1999). Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam- cyclodextrin system. Drug Dev. Ind. Pharm. 25: 279-287.
18. Loftson T, Brewster ME (1996). Pharmaceutical applications of cyclodextrins.1. Drug solubilization and stabilization. J. Pharm. Sci. 85: 1017-1025.
19. Luft B, Hafner R, Korzun A (1993). Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. New. Engl. J. Med. 329: 995-1000.
20. Nallury BN, Chowdary KP, Murthy KV, Hayman AR, Becker G (2003). Physicochemical characterization and dissolution properties of numesulide-cyclodextrin binary systems. AAPS Pharm. Sci. Technol. 4(1): 1-12.
21. Onyeji CO, Omoruyi SI, Oladimeji FA (2007). Dissolution properties and characterization of halofantrine-2-hydroxypropyl-b-cyclodextrin binary systems. Pharmazie 62: 858-863.
22. Pose-Vilarnovo B, Perdomo-Lopez I, Echezarreta-Lopez M, Schroth- Pardo P, Estrada E, Torres-Labandeira JJ (2001). Improvement of water solubility of sulfamethizole through its complexation with beta- and hydroxypropyl-beta- cyclodextrin. Characterization of the interaction in solution and in solid state. Eur. J. Pharm. Sci. 13(3): 325-331.
23. Richards FO, Kovacs JA, Luft BJ (1995). Preventing toxoplasmic encephalitis in persons infected with human-immunodeficiency-virus. Clin. Infect. Dis. 21(Suppl. 1): 49-56.
24. Ryan JA (1986). Compressed pellet x-ray diffraction monitoring for optimization of crystallinity in lyophilized solids: imipenem:cilastin sodium case. J. Pharm. Sci. 75: 805-807.
25. Szejtli J (1988). Cyclodextrin. In: Szejtli J (Ed.) Cyclodextrin Techno-logy. Kluwer Academic Publishers, Dordecht, pp. 45-82.
26. Sirawaraporn W, Yuthavong (1986). Potentiating Effect of Pyrimetha- mine and Sulfadoxine against Dihydrofolate Reductase from Pyrimethamine-Sensitive and Pyrimethamine-Resistant Plasmodium chabaudi. Antimicrob. Agent Chemother. 29(5): 899-905.
27. Uekama K, Hirayama F (1996). In: Wermuth CG (ed.). The Practice of Medicinal Chemistry. Academic Press, London, pp. 793-825.
28. Uekama K, Hirayama F, Irie T (1998). Cyclodextrin drug carrier systems. Chem. Rev. 98: 2045-2076.
29. Uekama K, Hirayama F, Mura P, Adragna E, Rabasco AM, Moyano JR, Perez-Martinez JL, Arias MJ, Gines JM (1999). Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin system. Drug Dev. Ind. Pharm. 25: 279-287.
30. United States Pharmacopoeia and National Formulary, United States Pharmacopeial Convention Inc, Rockville, MD, USA, 26th Edition (USP)(2003).
31. Viega F, Fernandes C, Maincent P (2001). Influence of the preparation method on the physicochemical properties of tolbutamide/ cyclodextrin binary systems. Drug Dev. Ind. Pharm. 27: 523-532.
32. Winstanley PA, Khoo S, Szwandt S, Edwards G, Wilkins E, Tjia J, Coker R (1995). Marked variation in pyrimethamine disposition in AIDS patients treated for cerebral toxoplasmosis. J. Antimicrob. Chemother. 36: 435-439.
33. Yalkowsky SH (Eds). Techniques of solubilization. Marcel Dekker Inc: NewYork, 1983.
34. Yamada Y, Imal T, Ouchi K, Otagiri M, Hirayam F, Eukama K (2000). Inclusion complex of 3,9-Bis(N,N dimethylcarbomoyloxy)5H- benzofuro] 3,2-c]-quinoline-6-one (kc A-098) with Heptakis(2,6-di-O- methyl)-β- cyclodextrin: Interaction and dissolution properties. Chem. Pharm. Bull 48(9): 1264-1268.